OMGAQ — Omega Liquidating Share News
0.000.00%
Last trade - 00:00- $0.17m
- -$14.62m
- $3.09m
Wegovy maker Novo Nordisk signs research partnerships with U.S. biotech firms
Brief: Omega Therapeutics Reports Third Quarter 2023 Financial Results And Highlights Recent Company Progress
Brief: Omega Therapeutics Presents New Preclinical Data
Brief: Omega Therapeutics Announces Promising Preliminary Clinical Data For Otx-2002 From Ongoing Mychelangelo I Trial
Brief: Omega Therapeutics - Co And Pacific Western Bank Entered Into Fifth Amendment To Loan And Security Agreement
Brief: Omega Therapeutics Reports Preclinical Data Showing The Potential Of Omega Epigenomic Controllers To Synergize With Immunotherapies
Brief: Omega Therapeutics Reports First Quarter 2023 Financial Results And Highlights Recent Company Progress
Brief: Omega Therapeutics Announces Clinical Supply Agreement To Evaluate The Combination Of OTX-2002 And Atezolizumab In Hepatocellular Carcinoma
Brief: Omega Therapeutics Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Corporate Update
Brief: Omega Therapeutics Inc - Offering 6.9 Million Shares Of Our Common Stock In A Registered Direct Offering
Brief: Omega Therapeutics Announces $40 Million Registered Direct Offering Of Common Stock
Brief: Omega Therapeutics To Present Data From Early-To-Mid Stage Mychelangelo I Study
Brief: Omega Therapeutics Inc Files For Mixed Shelf Of Up To $200 Million - SEC Filing
Brief: Omega Therapeutics Reports Third Quarter Financial Results
Brief: Omega Therapeutics Receives Orphan Drug Designation For Otx-2002 For Treatment Of Hepatocellular Carcinoma
Omega Therapeutics gains as dosing begins in cancer therapy study
Brief: Omega Therapeutics Announces First Patient Dosed In Landmark Mychelangelo™ I Trial Of Otx-2002 In Hepatocellular Carcinoma And Other Solid Tumor Types Associated With The Myc Oncogene
Brief: Omega Therapeutics Entered Into A Collaboration And License Agreement With Nitto Denko Corp
Brief: Omega Therapeutics Unveils New Epigenomic Controller Development Candidate Targeting Myc-Driven Non-Small Cell Lung Cancer